...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Drug resistance updates: reviews and commentaries in antimicrobial and anticancer chemotherapy >New cancer therapeutics: target-specific in, cytotoxics out?
【24h】

New cancer therapeutics: target-specific in, cytotoxics out?

机译：新的癌症疗法：靶标特异性进入，细胞毒性消除？

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The International Conference on Molecular Targets and Therapeutics, jointly sponsored by the American Association for Cancer Research (AACR), National Cancer Institute (NCI) and European Organization for Research and Treatment of Cancer (EORTC), was held in Boston on November 17-21, 2003. It offered updates of the latest developments and emerging trends in anti-cancer research. One of the most exciting areas was the development of molecular target-specific therapeutics that have the potential to maximize therapeutic benefit while minimizing toxicity to normal cells. Signifying the coming of age of tumour-specific targets and agents was the recurring theme, to urgently develop and validate biomarker assays as surrogate endpoints; both for showing that targeted agents act as expected and for providing proof of concept in the scientific rationale of new agents. Given the dominance of protein tyrosine kinase inhibitors in small-molecule drug design, a strong case was made for the implementation of phospho-proteomics or signal transduction signatures and pharmaco-proteomics or chemotherapeutic scans in phase I/II trials--or for the future "Nanolab", eloquently described by Leroy Hood. However, molecular targeted agents-other than imanitib (Gleevec)--have yet to enter broad clinical use and several presentations described efforts for improving classical (cytotoxic) chemotherapeutic agents by targeting them selectively to tumour cells.
机译：由美国癌症研究协会（AACR），美国国家癌症研究所（NCI）和欧洲癌症研究与治疗组织（EORTC）联合主办的国际分子靶标和治疗学会议于11月17日至21日在波士顿举行，2003年。它提供了抗癌研究的最新进展和新兴趋势的更新。最激动人心的领域之一是开发分子靶标特异性疗法，该疗法具有最大化治疗益处，同时最大程度降低对正常细胞的毒性的潜力。反复出现的主题是标志着肿瘤特异性靶标和药物时代的到来，以紧急开发和验证生物标志物测定法作为替代终点;既用于表明目标代理商的行为符合预期，也用于在新代理商的科学原理中提供概念证明。考虑到蛋白质酪氨酸激酶抑制剂在小分子药物设计中的主导地位，在I / II期试验中或将来为实施磷酸蛋白质组学或信号转导签名以及药物蛋白质组学或化学疗法扫描提供了强有力的证据“ Nanolab”，由Leroy Hood雄辩地描述。然而，除伊马替尼（Gleevec）以外的分子靶向药物尚未进入广泛的临床应用，一些报告介绍了通过选择性地将其靶向肿瘤细胞来改善经典（细胞毒性）化疗药物的努力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号